JungJin SEO, Honorary Chairman of Celltrion Group
JungJin SEO
South Korean entrepreneur JungJin SEO knew very little about science before founding a biopharmaceutical firm in 2003. Having lost his job at an automaker, he set up Celltrion at the age of 45 after hearing a scientist talk about the future of medicine. Today, the business is a multibillion-dollar global pharmaceutical company, developing groundbreaking drugs to treat cancer, autoimmune diseases and COVID-19.
JungJin spotted the potential of biosimilars — affordable biologic products highly similar to already approved biological drugs — and began researching them by interviewing scientists. He led his team to develop biosimilars to original monoclonal antibody treatments that mimic the body’s natural antibodies. Celltrion launched its first biosimilar drug, Remsima, for the treatment of autoimmune diseases, followed by drugs for breast cancer and lymphoma that are now used worldwide.
JungJin believes his industry has a duty to act in the interest of the country at a time of crisis. Celltrion has led the field in developing an antibody treatment for COVID-19, which was approved for use in South Korea in February 2021. Passionate about putting an end to the pandemic, JungJin is doing his part by offering the treatment to Koreans at production cost.
*Information correct as of June 2021.
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
EY | Assurance | Consulting | Strategy and Transactions | Tax
About EY
EY is a global leader in assurance, consulting, strategy and transactions, and tax services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.
© 2020 EYGM Limited. All Rights Reserved.
EYG/OC/FEA no.
ED MMYY
This material has been prepared for general informational purposes only and is not intended to be relied upon as accounting, tax, or other professional advice. Please refer to your advisors for specific advice.
In addition to cookies that are strictly necessary to operate this website, we use the following types of cookies to improve your experience and our services: Functional cookies to enhance your experience (e.g. remember settings), Performance cookies to measure the website's performance and improve your experience, Marketing/Targeting cookies which are set by third parties with whom we execute marketing campaigns and allow us to provide you with content relevant to you.
We have detected that you have enabled the Do Not Track setting in your browser; as a result, Marketing/Targeting cookies are automatically disabled.
You may withdraw your consent to cookies at any time once you have entered the website through a link in the privacy policy, which you can find at the bottom of each page on the website.
Review our cookie policy for more information.
I decline optional cookies